SCHEMBL6906930

SCHEMBL6906930

NS(=O)(=O)c1cc(Cl)c(O)c(S(N)(=O)=O)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 15/20 0.69
CA2 P00918 15/20 0.69
CA9 Q16790 14/20 0.66
CA12 O43570 9/20 0.66
CA4 P22748 5/20 0.66
CA6 P23280 5/20 0.66
CA5A P35218 5/20 0.66
CA7 P43166 5/20 0.66
CA14 Q9ULX7 5/20 0.66
CA5B Q9Y2D0 5/20 0.66
CA13 Q8N1Q1 3/20 0.66
APEX1 P27695 2/20 0.66
LMNA P02545 1/20 0.66
CYP2C9 P11712 1/20 0.66
POLB P06746 1/20 0.66
TDP1 Q9NUW8 1/20 0.66
L3MBTL1 Q9Y468 1/20 0.66
CYP2C19 P33261 1/20 0.52
PTGS1 P23219 1/20 0.45
PTGS2 P35354 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5564627 0.87 CA1 (0.64) CA1CA2CA9CA12CA4
SCHEMBL31070438 0.82 CA1 (1.00) CA1CA2CA9CA12F2
SCHEMBL9463563 0.82 CA1 (0.63) CA1CA2CA9CA12CA4
SCHEMBL1804698 0.82 CA1 (1.00) CA1CA2CA9CA12F2
Dichlorphenamide SCHEMBL112376 0.79 CA1 (1.00) CA1CA2CA9CA12CA4
Dichlorphenamide SCHEMBL29355725 0.79 CA1 (1.00) CA1CA2CA9CA12CA4
SCHEMBL9518035 0.79 APEX1 (1.00) CA1CA2CA9CA12CA4
SCHEMBL22022107 0.78 CA1 (0.67) CA1CA2
SCHEMBL29780561 0.78 CA2 (0.65) CA1CA2CA9CA12CA4
Dichlorphenamide SCHEMBL4312398 0.78 CA1 (0.96) CA1CA2CA9CA12CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040186155-A1 Combination therapy for the treatment or prevention of migraine DAYNO JEFFREY MARC (US) 2004-09-23 US disclosed
EP-0276057-B1 Piperazinylpyrimidines as beta-adrenergic receptor blocking agents MERCK & CO INC (US) 1994-03-09 EP disclosed
US-5157044-A Treating glaucoma UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 1992-10-20 US disclosed
US-5095026-A PRODRUGS OF CARBONIC ANHYDRASE INHIBITORS UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 1992-03-10 US disclosed
EP-0295049-B1 THIOPHENE SULFONAMIDE ANTIGLAUCOMA AGENTS MERCK & CO. INC. (US) 1991-10-09 EP disclosed
US-4994464-A Treatment of elevated intraocular pressure and glaucoma MERCK & CO., INC. (US) 1991-02-19 US disclosed
EP-0122831-B1 BENZOTHIAZOLE-2-SULFONAMIDE DERIVATIVES FOR THE TOPICAL TREATMENT OF ELEVATED INTRAOCULAR PRESSURE MERCK & CO. INC. (US) 1990-04-18 EP disclosed
US-4889856-A INTRAOCULAR PRESSURE REDUCTION; CARDIOVASCULAR DISORDERS MERCK & CO., INC. (US) 1989-12-26 US disclosed
US-4847289-A Thiophene sulfonamide antiglaucoma agents MERCK & CO., INC. (US) 1989-07-11 US disclosed
EP-0295049-A2 Thiophene sulfonamide antiglaucoma agents MERCK & CO. INC. (US) 1988-12-14 EP disclosed
EP-0276057-A2 Piperazinylpyrimidines as beta-adrenergic receptor blocking agents MERCK & CO. INC. (US) 1988-07-27 EP disclosed
US-4499103-A Benzothiazole-2-sulfonamide derivatives for the topical treatment of elevated intraocular pressure MERCK & CO., INC. (US) 1985-02-12 US disclosed
EP-0122831-A2 Benzothiazole-2-sulfonamide derivatives for the topical treatment of elevated intraocular pressure MERCK & CO. INC. (US) 1984-10-24 EP disclosed
US-4045558-A Pilocarpine salts MERCK & CO., INC. (US) 1977-08-30 US disclosed
US-4045558-A Pilocarpine salts MERCK & CO., INC. (US) 1977-08-30 US disclosed